New combo therapy shows promise for tough liver cancer
NCT ID NCT04238637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding immunotherapy drugs (durvalumab and tremelimumab) to a type of internal radiation therapy (Y-90 SIRT) can shrink tumors in people with advanced bile duct cancer that has not spread beyond the liver. About 50 adults with this rare liver cancer will receive the combination treatment. The goal is to see if the immune system can be boosted to better fight the cancer while radiation targets the tumor directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinic Essen Center
Essen, Germany
-
Hannover Medical School
Hanover, Germany
-
Munich Clinic Bogenhausen
Munich, Germany
-
University Hospital Dresden
Dresden, Germany
-
University Hospital Essen
Essen, Germany
-
University Hospital Halle
Halle, Germany
-
University Hospital Jena
Jena, Germany
-
University Hospital Munich Grosshadern
Munich, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Triple attack on bile duct cancer: chemo, targeted drug, and immunotherapy aim to make the inoperable operable